Quick Answer
Solid Biosciences Inc. reported Total Revenue of $8.09 million for fiscal year 2022.
Solid Biosciences Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $8.09M -40.6% |
$13.62M | $0.00 |
| Net Income | — | — | — | — | — | — |
| Diluted EPS | -$1.99 +35.0% |
-$3.06 +36.6% |
-$4.83 +52.2% |
-$10.10 +0.4% |
-$10.14 +60.2% |
-$25.50 |
| Total Assets | $232.54M +23.3% |
$188.66M +14.4% |
$164.94M -36.6% |
$260.25M +12.0% |
$232.38M +35.8% |
$171.17M +65.4% |
| Cash and Equivalents | $59.90M -25.3% |
$80.23M +8.4% |
$74.02M -52.4% |
$155.38M +30.4% |
$119.14M -23.0% |
$154.74M +103.5% |
| Stockholders Equity | $180.01M +31.2% |
$137.25M +8.5% |
$126.48M -40.2% |
$211.67M +1.7% |
$208.21M +57.6% |
$132.09M +65.0% |
| R&D Expense | $140.32M +45.5% |
$96.43M +25.9% |
$76.56M -2.4% |
$78.42M +33.5% |
$58.74M -9.5% |
$64.88M -31.5% |
| Operating Income | -$179.21M -38.1% |
-$129.73M -24.4% |
-$104.25M +2.1% |
-$106.45M -47.3% |
-$72.25M +18.3% |
-$88.41M +25.9% |
| Shares Outstanding | 78.97M +95.1% |
40.47M +98.5% |
20.39M +4.2% |
19.56M +165.9% |
7.36M -91.3% |
84.89M +84.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2020 | $0.00 | — | — |
| Net Income | September 30, 2021 | -$17.98M | +15.4% | +3.8% |
| Diluted EPS | September 30, 2025 | -$0.48 | +39.2% | -14.3% |
| Total Assets | September 30, 2025 | $273.91M | +29.3% | -11.2% |
| Cash and Equivalents | September 30, 2025 | $61.36M | -4.7% | -55.8% |
| Stockholders Equity | September 30, 2025 | $217.95M | +30.5% | -15.6% |
| R&D Expense | September 30, 2025 | $38.86M | +42.2% | +19.9% |
| Operating Income | September 30, 2025 | -$48.06M | -36.6% | -15.3% |
| Shares Outstanding | September 30, 2025 | 77.88M | +100.1% | +0.4% |
- Solid Biosciences Inc. reported Total Revenue of $8.09 million for fiscal year 2022.
- Solid Biosciences Inc. showed a decrease of -40.6% in Total Revenue compared to the prior fiscal year.
- Solid Biosciences Inc. reported Net Income of -$117.22 million for fiscal year 2019.
- Solid Biosciences Inc. showed a decrease of -56.7% in Net Income compared to the prior fiscal year.
- Solid Biosciences Inc. reported Diluted EPS of $1.99 per share (loss) for fiscal year 2025.
- Solid Biosciences Inc. showed an increase of +35.0% in Diluted EPS compared to the prior fiscal year.
- Solid Biosciences Inc. reported Total Assets of $232.54 million for fiscal year 2025.
- Solid Biosciences Inc. showed an increase of +23.3% in Total Assets compared to the prior fiscal year.
- Solid Biosciences Inc. reported Cash and Equivalents of $59.90 million for fiscal year 2025.
- Solid Biosciences Inc. showed a decrease of -25.3% in Cash and Equivalents compared to the prior fiscal year.
- Solid Biosciences Inc. reported Stockholders Equity of $180.01 million for fiscal year 2025.
- Solid Biosciences Inc. showed an increase of +31.2% in Stockholders Equity compared to the prior fiscal year.
- Solid Biosciences Inc. reported R&D Expense of $140.32 million for fiscal year 2025.
- Solid Biosciences Inc. showed an increase of +45.5% in R&D Expense compared to the prior fiscal year.
- Solid Biosciences Inc. reported Operating Income of -$179.21 million for fiscal year 2025.
- Solid Biosciences Inc. showed a decrease of -38.1% in Operating Income compared to the prior fiscal year.
- Solid Biosciences Inc. reported Shares Outstanding of 78.97 million shares for fiscal year 2025.
- Solid Biosciences Inc. showed an increase of +95.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: